A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Lurasidone (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions
- Sponsors Sumitomo Dainippon Pharma
- 23 Mar 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2017 This trial was completed in Lithuania, according to European Clinical Trials Database.
- 21 Feb 2017 Status changed from recruiting to active, no longer recruiting.